GetTopicDetailResponse(id=e7b7256894b, topicName=伏立諾他, introduction=伏立諾他, content=null, image=null, comments=1, allHits=2011, url=https://h5.medsci.cn/topic?id=25689, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=11068, tagList=[TagDto(tagId=11068, tagName=伏立諾他)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=896954, encodeId=3b8e89695463, content=<a href='/topic/show?id=e7b7256894b' target=_blank style='color:#2F92EE;'>#伏立諾他#</a>（vorinostat）和mTOR抑制劑<a href='/topic/show?id=73a8988297a' target=_blank style='color:#2F92EE;'>#雷帕霉素#</a>（V+S）方案雖好，可能會(huì)被免疫治療方案取代！PD-1/PD-L1對(duì)復(fù)發(fā)/難治性<a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a>效果相當(dāng)?shù)暮?，未?lái)可能會(huì)考慮與這兩種藥物進(jìn)行適當(dāng)?shù)慕M合, objectTitle=Clin Cancer Res：HDAC和mTOR聯(lián)合抑制大大改善復(fù)發(fā)/難治性霍奇金淋巴瘤患者預(yù)后, objectType=article, longId=202902, objectId=3b6b202902d9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/193.jpg, objectUrl=/article/show_article.do?id=3b6b202902d9, replyNumber=0, likeNumber=324, createdTime=2020-11-04, rootId=0, userName=仁醫(yī)06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b6b202902d9, moduleTitle=Clin Cancer Res：HDAC和mTOR聯(lián)合抑制大大改善復(fù)發(fā)/難治性霍奇金淋巴瘤患者預(yù)后, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3b6b202902d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
